Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Ghana FDA approves Vanessa for antidiarrheal trials

Vanessa Biotech has been granted regulatory approval from the Ghana FDA to conduct Phase 2 clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug. The Phase...

| By Kelley Gipson

New Haven bio poised for boom, leaders say

Bioscience leaders outlined the challenges of bringing their discoveries to market and growing in New Haven as part of a panel discussion with public officials...

| By Kelley Gipson

Artizan names Dr. Bridget Martell CEO

New Haven-based Artizan Biosciences recently appointed Dr. Bridget Martell to serve as the company’s new president and CEO. Martell has an extensive background in the...

| By Kelley Gipson

Alexion has opened new doors re rare diseases

Scientists at Alexion have made it their mission to pioneer new scientific breakthroughs to transform the treatment of rare diseases and devastating conditions. But delivering...

| By Kelley Gipson

AstraZeneca’s Alexion adds to rare disease pipepline

Following its acquisition by drug giant AstraZeneca, New Haven-born Alexion Pharmaceuticals is growing its drug pipeline, agreeing to pay up to $500 million for New Jersey-based Caelum...

| By Kelley Gipson

Branford’s IsoPlexis makes Wall Street debut

IsoPlexis, a Branford-based life science technology company, went public in early October, with its stock initially trading at $15 a share. The company’s stock is listed...

| By Kelley Gipson

Yale Blavatnik Fund eyes digital health

A five-year-old Yale program that has helped dozens of drug and medical device companies get their ideas off the ground is now looking to help...

| By Kelley Gipson

UConn advances in Alzheimer’s and bone disease

UConn Associate Professor of Medicine Anne Delany has received a $2.2 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to...

| By Kelley Gipson

Biorez awarded patents re BioBrace™ technology

Biorez reports four new patents relating to Biorez’s proprietary BioBrace™ Implant, which is a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a...

| By Kelley Gipson

CT R&D tax credit best in U.S. — but only if …

By Bill Claffey, tax attorney and partner at the accounting firm Fiondella, Milone and LaSaracina LLP (FML) The Connecticut R&D tax credit allows corporations to...